Ivan Lew, executive director and CEO of Biolidics, with the company's patented technology that can separate cancer cells from blood to test for the presence of cancer.
Singapore
MEDICAL technology company Biolidics on Tuesday launched an initial public offering (IPO) of 27.5 million new shares at S$0.28 each. The placement is in conjunction with its proposed listing on the Catalist board on Dec 19.
Register to read this article. Log in if you are already a subscriber.Register to read this article. Log in if you are already a subscriber.Please log in or subscribe to continue reading.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes